(GLP-1)
GLP-1 RECEPTOR AGONIST
A Science-Backed Approach to Weight Management and Metabolic Health
1,000 + Patients Served
24 /7 Telehealth Access
15 + Treatments Available
98 % Patient Satisfaction
Overview
(GLP-1) receptor agonist with established FDA approvals for type 2 diabetes management, chronic weight management, and cardiovascular risk reduction in adults with obesity or overweight. It represents a transformative option for patients seeking clinically meaningful, sustained weight loss and metabolic improvement.
FDA-Approved Indications
Mean weight reductions of 14.9–17.4% at 68 weeks in STEP trials
Reduction of major adverse cardiovascular events in adults with CVD
Type 2 diabetes glycemic control
Chronic weight management (BMI ≥30, or ≥27 with comorbidity)
Clinical Rationale
Semaglutide exerts therapeutic effects through:
Delayed gastric emptying and increased satiety signaling
Enhanced glucose-dependent insulin secretion and suppressed glucagon
Cardiometabolic risk factor improvement independent of weight loss
Central appetite regulation reducing caloric intake
These mechanisms address the physiologic drivers of obesity and metabolic dysfunction.
Administration
Subcutaneous injection once weekly with dose escalation (0.25 mg → 2.4 mg over 16–20 weeks) to optimize tolerability. Vial for reconstitution with bacteriostatic water (multiple-dose). Oral formulations available.
Wellness & Regenerative Focus
Semaglutide is positioned as a cornerstone therapy for comprehensive metabolic health—addressing obesity as a chronic, relapsing disease with substantial cardiometabolic morbidity when combined with lifestyle intervention and ongoing medical management.
IMPORTANT SAFETY INFORMATION: Semaglutide may cause serious side effects, including pancreatitis, gallbladder problems, kidney injury, and possible thyroid tumors, including cancer. Not for use in pregnancy. Please discuss risks and benefits with your healthcare provider.